186 related articles for article (PubMed ID: 18482958)
21. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
Pinheiro Edos S; Antunes OA; Fortunak JM
Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
[TBL] [Abstract][Full Text] [Related]
22. Update on HAART in HIV.
Yeni P
J Hepatol; 2006; 44(1 Suppl):S100-3. PubMed ID: 16359748
[TBL] [Abstract][Full Text] [Related]
23. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG
AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903
[TBL] [Abstract][Full Text] [Related]
24. Improving non-nucleoside reverse transcriptase inhibitors for first-line treatment of HIV infection: the development pipeline and recent clinical data.
Sweeney ZK; Klumpp K
Curr Opin Drug Discov Devel; 2008 Jul; 11(4):458-70. PubMed ID: 18600563
[TBL] [Abstract][Full Text] [Related]
25. Short-term randomized proof-of-principle trial of TMC278 in patients with HIV type-1 who have previously failed antiretroviral therapy.
Arastéh K; Rieger A; Yeni P; Pozniak A; Boogaerts G; van Heeswijk R; de Béthune MP; Peeters M; Woodfall B
Antivir Ther; 2009; 14(5):713-22. PubMed ID: 19704175
[TBL] [Abstract][Full Text] [Related]
26. Clinical evidence of interaction between itraconazole and nonnucleoside reverse transcriptase inhibitors in HIV-infected patients with disseminated histoplasmosis.
Andrade RA; Evans RT; Hamill RJ; Zerai T; Giordano TP
Ann Pharmacother; 2009 May; 43(5):908-13. PubMed ID: 19401476
[TBL] [Abstract][Full Text] [Related]
27. Are all non-thymidine analogue backbones appropriate for treating antiretroviral-naïve patients?
Waters LJ; Nelson MR
Int J Clin Pract; 2005 Dec; 59(12):1452-8. PubMed ID: 16351678
[TBL] [Abstract][Full Text] [Related]
28. Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India.
Kandathil AJ; Kannangai R; Verghese VP; Pulimood SA; Rupali P; Sridharan G; Grant P; Pillay D; Abraham OC
Indian J Med Microbiol; 2009; 27(3):231-6. PubMed ID: 19584504
[TBL] [Abstract][Full Text] [Related]
29. Costs associated with combination antiretroviral therapy in HIV-infected patients.
Yazdanpanah Y
J Antimicrob Chemother; 2004 Apr; 53(4):558-61. PubMed ID: 14985277
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness and durability of non-nucleoside reverse transcriptase inhibitor-based therapy in HIV clinical practice.
Kan VL
AIDS; 2007 Apr; 21(7):880-2. PubMed ID: 17415048
[No Abstract] [Full Text] [Related]
31. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
Cuzin L; Allavena C; Morlat P; Dellamonica P
AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976
[TBL] [Abstract][Full Text] [Related]
32. Assessing efficiency and costs of scaling up HIV treatment.
Cleary SM; McIntyre D; Boulle AM
AIDS; 2008 Jul; 22 Suppl 1():S35-42. PubMed ID: 18664951
[TBL] [Abstract][Full Text] [Related]
33. The picture of future therapy.
Gazzard B
Int J Clin Pract Suppl; 1999 Jun; 103():45-8. PubMed ID: 10622045
[TBL] [Abstract][Full Text] [Related]
34. Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses.
Chou R; Fu R; Huffman LH; Korthuis PT
Lancet; 2006 Oct; 368(9546):1503-15. PubMed ID: 17071284
[TBL] [Abstract][Full Text] [Related]
35. Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000-2010.
Fidan D; Unal B; Critchley J; Capewell S
QJM; 2007 May; 100(5):277-89. PubMed ID: 17449875
[TBL] [Abstract][Full Text] [Related]
36. The cost-effectiveness of early access to HIV services and starting cART in the UK 1996-2008.
Beck EJ; Mandalia S; Sangha R; Sharott P; Youle M; Baily G; Brettle R; Gompels M; Johnson M; McCarron B; Ong E; Pozniak A; Schwenk A; Taylor S; Walsh J; Wilkins E; Williams I; Gazzard B;
PLoS One; 2011; 6(12):e27830. PubMed ID: 22194795
[TBL] [Abstract][Full Text] [Related]
37. Assessment of antiretroviral third agent virologic durability after initiation of first antiretroviral regimen.
Varriano B; Sandler I; Loutfy M; Steinberg S; Smith G; Kovacs C; Brunetta J; Fletcher D; Knox D; Merkley B; Chang B; Tilley D; Acsai M; Crouzat F
Int J STD AIDS; 2019 Jun; 30(7):680-688. PubMed ID: 31042101
[TBL] [Abstract][Full Text] [Related]
38. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S
Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038
[TBL] [Abstract][Full Text] [Related]
39. [Antiretroviral therapy 2003. The current status].
Jablonowski H
MMW Fortschr Med; 2003 Apr; 145 Spec No 1():4-8. PubMed ID: 15011574
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia.
Long EF; Brandeau ML; Galvin CM; Vinichenko T; Tole SP; Schwartz A; Sanders GD; Owens DK
AIDS; 2006 Nov; 20(17):2207-15. PubMed ID: 17086061
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
